107 related articles for article (PubMed ID: 24888847)
1. Glycolysis inhibition and its effect in doxorubicin resistance in neuroblastoma.
Bean JF; Qiu YY; Yu S; Clark S; Chu F; Madonna MB
J Pediatr Surg; 2014 Jun; 49(6):981-4; discussion 984. PubMed ID: 24888847
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
[TBL] [Abstract][Full Text] [Related]
3. Differential drug sensitivity of human neuroblastoma cells.
Spengler BA; Ross RA; Biedler JL
Cancer Treat Rep; 1986 Aug; 70(8):959-65. PubMed ID: 3731152
[TBL] [Abstract][Full Text] [Related]
4. The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.
Levy AG; Zage PE; Akers LJ; Ghisoli ML; Chen Z; Fang W; Kannan S; Graham T; Zeng L; Franklin AR; Huang P; Zweidler-McKay PA
Invest New Drugs; 2012 Feb; 30(1):191-9. PubMed ID: 20890785
[TBL] [Abstract][Full Text] [Related]
5. [Effect of 3-bromopyruvate on mitochondrial membrane potential and apoptosis of human breast carcinoma SK-BR-3 cells].
Zhang Y; Liu Z; Zhang Q; Chao Z; Zhang P; Xia F; Jiang C; Liu H; Jiang Z
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Sep; 33(9):1304-7. PubMed ID: 24067208
[TBL] [Abstract][Full Text] [Related]
6. PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin.
Julson JR; Quinn CH; Nazam N; Bownes LV; Stewart JE; Beierle EA
J Pediatr Surg; 2024 Jul; 59(7):1334-1341. PubMed ID: 38570263
[TBL] [Abstract][Full Text] [Related]
7. Glycolysis inhibitors as a potential therapeutic option to treat aggressive neuroblastoma expressing GLUT1.
Matsushita K; Uchida K; Saigusa S; Ide S; Hashimoto K; Koike Y; Otake K; Inoue M; Tanaka K; Kusunoki M
J Pediatr Surg; 2012 Jul; 47(7):1323-30. PubMed ID: 22813791
[TBL] [Abstract][Full Text] [Related]
8. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
Iwasaki I; Sugiyama H; Kanazawa S; Hemmi H
Cancer Chemother Pharmacol; 2002 Jun; 49(6):438-44. PubMed ID: 12107547
[TBL] [Abstract][Full Text] [Related]
9. Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics.
Zheng X; Naiditch J; Czurylo M; Jie C; Lautz T; Clark S; Jafari N; Qiu Y; Chu F; Madonna MB
Cell Death Dis; 2013 Jul; 4(7):e740. PubMed ID: 23887631
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo preclinical chemotherapy studies of human neuroblastoma.
Siegel MM; Chung HS; Rucker N; Siegel SE; Seeger RC; Isaacs H; Benedict WF
Cancer Treat Rep; 1980; 64(8-9):975-9. PubMed ID: 7448832
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate.
Pereira da Silva AP; El-Bacha T; Kyaw N; dos Santos RS; da-Silva WS; Almeida FC; Da Poian AT; Galina A
Biochem J; 2009 Feb; 417(3):717-26. PubMed ID: 18945211
[TBL] [Abstract][Full Text] [Related]
12. DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs.
Charlet J; Schnekenburger M; Brown KW; Diederich M
Biochem Pharmacol; 2012 Apr; 83(7):858-65. PubMed ID: 22280814
[TBL] [Abstract][Full Text] [Related]
13. Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance.
Ridinger J; Koeneke E; Kolbinger FR; Koerholz K; Mahboobi S; Hellweg L; Gunkel N; Miller AK; Peterziel H; Schmezer P; Hamacher-Brady A; Witt O; Oehme I
Sci Rep; 2018 Jul; 8(1):10039. PubMed ID: 29968769
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells.
Hopkins-Donaldson S; Yan P; Bourloud KB; Muhlethaler A; Bodmer JL; Gross N
Oncogene; 2002 Sep; 21(39):6132-7. PubMed ID: 12203125
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin resistant neuroblastoma cells secrete factors that activate AKT and attenuate cytotoxicity in drug-sensitive cells.
Emran MA; Rebbaa A; Mirkin BL
Cancer Lett; 2002 Aug; 182(1):53-9. PubMed ID: 12175523
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
Keshelava N; Seeger RC; Groshen S; Reynolds CP
Cancer Res; 1998 Dec; 58(23):5396-405. PubMed ID: 9850071
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia.
Xu RH; Pelicano H; Zhou Y; Carew JS; Feng L; Bhalla KN; Keating MJ; Huang P
Cancer Res; 2005 Jan; 65(2):613-21. PubMed ID: 15695406
[TBL] [Abstract][Full Text] [Related]
18. Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression.
Kotchetkov R; Driever PH; Cinatl J; Michaelis M; Karaskova J; Blaheta R; Squire JA; Von Deimling A; Moog J; Cinatl J
Int J Oncol; 2005 Oct; 27(4):1029-37. PubMed ID: 16142320
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of heat shock proteins (HSP) expression by quercetin and differential doxorubicin sensitization in neuroblastoma and Ewing's sarcoma cell lines.
Zanini C; Giribaldi G; Mandili G; Carta F; Crescenzio N; Bisaro B; Doria A; Foglia L; di Montezemolo LC; Timeus F; Turrini F
J Neurochem; 2007 Nov; 103(4):1344-54. PubMed ID: 17680992
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin increases oxidative metabolism in HL-1 cardiomyocytes as shown by 13C metabolic flux analysis.
Strigun A; Wahrheit J; Niklas J; Heinzle E; Noor F
Toxicol Sci; 2012 Feb; 125(2):595-606. PubMed ID: 22048646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
